Does Anthem Cover Novolog?

Understanding Anthem's Novolog Formulary Placement

Anthem Blue Cross Blue Shield includes Novolog (insulin aspart) on the majority of its commercial and government plan formularies. The exact tier depends on your plan's pharmacy benefit design, the state where you purchased coverage, and whether Anthem has negotiated preferred pricing with Novo Nordisk for your specific benefit group.

Insulin aspart, the active ingredient in Novolog, is a rapid-acting insulin analog first approved by the FDA in June 2000 for glycemic control in adults and children with Type 1 and Type 2 diabetes. The American Diabetes Association's 2024 Standards of Care recommend rapid-acting analogs like insulin aspart as the preferred mealtime insulin because of their faster onset (10 to 20 minutes) and shorter duration compared to regular human insulin [1]. This clinical preference means most large insurers, Anthem included, maintain at least one rapid-acting analog on formulary.

On Anthem's 2025-2026 national preferred formulary, Novolog FlexPen and Novolog vials appear on Tier 2 or Tier 3, depending on whether the plan has designated a competing product (such as Humalog or Admelog) as preferred [2]. Anthem plans in California, Georgia, Ohio, and Virginia frequently place Novolog on Tier 2 with copays between $30 and $50 for a 30-day supply. Plans in states where Anthem has contracted preferential pricing with Eli Lilly (for Humalog or its authorized generic) may push Novolog to Tier 3, raising copays to the $60 to $95 range.

You can verify your plan's specific formulary by logging into Anthem's pharmacy lookup tool and entering "insulin aspart" or "Novolog." According to the Centers for Medicare & Medicaid Services (CMS), all Medicare Part D plans must cover at least one insulin in each dosage form and category, which guarantees access to rapid-acting insulin for Medicare Advantage members enrolled in Anthem plans.

How Much Novolog Costs With Anthem Insurance

The price you pay at the pharmacy counter depends on your plan tier, deductible structure, and whether federal or state insulin cost caps apply to your coverage type. A patient with unmet deductible on a high-deductible health plan (HDHP) could temporarily face the full negotiated price before cost-sharing kicks in.

The average wholesale acquisition cost (WAC) for a 10 mL vial of Novolog is roughly $289, and a box of five 3 mL FlexPens lists at approximately $543 [3]. After Anthem's negotiated discount, most members see a pharmacy price significantly below WAC. For Tier 2 placement, expect copays of $25 to $50 per 30-day fill. Tier 3 placement typically runs $50 to $95.

The Inflation Reduction Act (IRA) capped out-of-pocket insulin costs at $35 per month for all Medicare Part D beneficiaries starting January 1, 2023. This cap applies to Anthem's Medicare Advantage Prescription Drug (MAPD) plans regardless of tier placement [4]. The IRA also eliminated the Part D deductible for covered insulins, meaning Medicare members with Anthem pay no more than $35 from their first fill.

For commercial (employer-sponsored) plans, no federal cap exists yet, though multiple states have enacted insulin copay caps. Colorado's SB 19-005 limits insulin copays to $100 per 30-day supply for state-regulated plans [5]. Illinois, Maine, New Mexico, and over a dozen other states have enacted similar caps, many at $25 to $50 per month. If your Anthem plan is regulated by one of these states, the cap overrides whatever the formulary tier would otherwise require.

Anthem HDHP members should note that insulin is classified as a preventive drug under IRS Notice 2019-45, which allows HSA-compatible plans to cover insulin below the deductible. Many Anthem HDHP plans have adopted this provision, letting members access Novolog at their normal copay before hitting the deductible.

Prior Authorization and Step Therapy Requirements

Anthem does not typically require prior authorization (PA) for Novolog in members with a documented Type 1 diabetes diagnosis. PA requirements are more common in Marketplace and Medicaid managed-care plans, particularly when the plan designates a different rapid-acting insulin as preferred.

Step therapy protocols, when they apply, generally require the member to have tried or be currently using the plan's preferred rapid-acting insulin (often Humalog or Admelog) before Novolog is approved at a lower cost-sharing tier. The American Diabetes Association's position statement on insulin access argues against non-medical switching of insulin products, noting that forced switching can increase the risk of hypoglycemia and hyperglycemia during transition periods [6].

If your Anthem plan requires step therapy for Novolog, your prescriber can submit a coverage exception request. Anthem's exception process typically requires documentation that the preferred insulin caused adverse effects, failed to achieve glycemic targets, or is clinically inappropriate. The National Council on Prescription Drug Programs (NCPDP) standards require insurers to respond to standard exception requests within 72 hours and urgent (expedited) requests within 24 hours.

Quantity limits are standard across Anthem plans. Most plans cap fills at a 30-day supply for retail pharmacy and offer 90-day fills through mail order or preferred retail pharmacies. Members using insulin pumps may qualify for higher quantity limits by submitting pump settings and daily dose documentation. The FDA's prescribing information for Novolog does not specify a maximum dose, so quantity limit overrides are granted when clinical documentation supports the prescribed amount [7].

Novolog vs. Preferred Alternatives on Anthem Plans

Anthem's formulary strategy often favors one rapid-acting insulin over others based on rebate agreements with manufacturers. Knowing which product your plan prefers can save $20 to $60 per month without changing your clinical outcomes.

The three primary rapid-acting insulin analogs available in the United States are insulin aspart (Novolog), insulin lispro (Humalog and its biosimilar Admelog), and insulin glulisine (Apidra). A Cochrane systematic review of 57 randomized controlled trials (N=16,985) found no clinically significant differences in HbA1c reduction, hypoglycemia incidence, or patient satisfaction among these three rapid-acting analogs [8]. The 2024 ADA Standards of Care echo this finding, stating that the choice among rapid-acting analogs should be guided primarily by cost, availability, and patient preference [9].

On plans where Humalog or Admelog sits on Tier 2 and Novolog is on Tier 3, switching to the preferred product is the simplest cost reduction strategy. Admelog, an insulin lispro product manufactured by Sanofi, was approved as a follow-on biologic and is therapeutically equivalent to Humalog. When Anthem lists Admelog as the preferred rapid-acting insulin, copays often drop to the $25 to $35 range.

Novo Nordisk also manufactures insulin aspart biosimilar products marketed internationally. In the U.S., the FDA has approved insulin aspart injection (Novo Nordisk) as an interchangeable biosimilar, which pharmacists in most states can substitute without prescriber intervention. If your Anthem formulary lists the biosimilar at a lower tier, the switch happens automatically at the pharmacy unless your prescriber specifies "dispense as written."

How to Check Your Specific Anthem Plan's Coverage

Each Anthem plan has its own formulary document, and coverage details can change at the start of each plan year. A few steps will get you a definitive answer for your specific plan.

First, locate your plan's formulary. Anthem members can access this through the Sydney Health app or anthem.com member portal. Manage to "Pharmacy" or "Find a Medication" and search for "Novolog" or "insulin aspart." The result will show tier placement, any PA or step therapy requirements, and quantity limits specific to your plan. If you have an Anthem Medicare Advantage plan, CMS requires all plan formularies to be publicly searchable through Medicare Plan Finder [10].

Second, call Anthem's pharmacy benefits helpline (the number on the back of your member ID card). Ask specifically: (1) which tier Novolog is on, (2) whether prior authorization or step therapy applies, (3) what your copay or coinsurance is after deductible, and (4) whether any insulin cost cap applies to your plan.

Third, ask your pharmacist to run a test claim. This provides the exact out-of-pocket amount based on your current deductible status and benefit accumulation. Test claims reflect real-time adjudication, including any manufacturer copay card or discount already linked to your profile.

For members who discover Novolog on a higher tier than expected, Anthem allows formulary tier exception requests [11]. Your physician submits clinical documentation explaining why the preferred alternative is not appropriate. Approval moves Novolog to the next lower tier, reducing your copay. The success rate for insulin tier exceptions is relatively high when the request includes documentation of prior treatment failure, adverse effects, or specific pump compatibility requirements.

Saving Money on Novolog With Anthem

Even with insurance coverage, rapid-acting insulin represents a significant monthly expense for many patients. Several strategies can reduce your out-of-pocket spending beyond your standard Anthem copay.

Novo Nordisk's Patient Assistance Program (PAP) provides Novolog at no cost to uninsured patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level). For insured members, Novo Nordisk offers a copay savings card that may reduce out-of-pocket costs to as low as $25 per fill, though this card cannot be combined with Medicare, Medicaid, or other government-funded insurance [12].

The 340B Drug Pricing Program, administered by the Health Resources and Services Administration (HRSA), allows qualifying healthcare organizations to purchase Novolog at significant discounts and pass savings to eligible patients. If you receive care at a federally qualified health center (FQHC) or qualifying hospital outpatient department, ask whether 340B pricing applies to your insulin prescriptions [13].

Mail-order pharmacy through Anthem's preferred pharmacy benefit manager (typically Express Scripts or IngenioRx) often provides a 90-day supply for the cost of two monthly copays, effectively reducing per-month spending by one-third. Anthem plans that include a preferred retail 90-day option (available at CVS, Walgreens, and other chains) offer the same pricing without the wait for delivery.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective as of 2025, provides an additional safety net for Anthem Medicare members who use multiple diabetes medications [14]. Once total out-of-pocket drug spending hits $2,000 in a calendar year, all covered medications (including Novolog) cost $0 for the remainder of the year.

Clinical Considerations for Novolog Users

Novolog's pharmacokinetic profile makes it suitable for both injection-based and pump-based insulin delivery. Understanding these clinical details helps you advocate for appropriate coverage when dealing with insurance requirements.

Insulin aspart has an onset of action of 10 to 20 minutes, peak effect at 1 to 3 hours, and a duration of 3 to 5 hours according to its FDA-approved prescribing information [15]. This profile closely mirrors the body's natural mealtime insulin secretion, which is why rapid-acting analogs have largely replaced regular human insulin for prandial coverage. A meta-analysis published in The Lancet Diabetes & Endocrinology found that rapid-acting analogs reduce postprandial glucose excursions by 20 to 30 mg/dL more than regular human insulin, with a small but statistically significant reduction in severe hypoglycemia (relative risk 0.82, 95% CI 0.71 to 0.96) [16].

For insulin pump users, Novolog carries an FDA-approved indication for continuous subcutaneous insulin infusion (CSII). The Endocrine Society's clinical practice guideline on insulin pump therapy notes that rapid-acting analogs are the only insulins recommended for pump use, and that aspart and lispro perform comparably in this setting [17]. If your Anthem plan requires step therapy to a different rapid-acting analog and you use a pump, document your pump's compatibility specifications in the exception request. Some older pump models are validated only for specific insulin formulations.

Novolog Mix 70/30 (a premixed formulation containing 70% insulin aspart protamine and 30% insulin aspart) is a separate product with its own formulary line. Coverage and tier placement for the premixed formulation may differ from standard Novolog. The ADA Standards of Care note that premixed insulins are appropriate for patients who need simplified regimens but are willing to accept less dosing flexibility [18].

What to Do If Anthem Denies Novolog Coverage

A coverage denial does not mean you have no options. The appeals process is regulated by both federal and state law, and most insulin denials can be overturned with adequate clinical documentation.

If Anthem denies coverage or places Novolog at an unaffordable tier, your prescriber can file a formulary exception. Under CMS regulations (42 CFR §423.578) for Medicare plans and corresponding state regulations for commercial plans, insurers must provide a written explanation for any denial and inform you of your appeal rights [19]. First-level appeals are decided within 30 days (standard) or 72 hours (expedited) for Medicare plans. For commercial plans, state timelines vary but typically fall within 15 to 30 business days.

Strong exception requests include: documented hypoglycemia on the preferred alternative, HbA1c deterioration after a forced switch, allergic reaction to excipients in the preferred product, or pump incompatibility. The FDA Adverse Event Reporting System (FAERS) data show that insulin product switching is associated with a transient increase in glycemic variability, which your endocrinologist can cite as clinical justification for remaining on Novolog [20].

If the internal appeal fails, external review is available. The Affordable Care Act (ACA) guarantees access to independent external review for all non-grandfathered health plans. An independent review organization evaluates the clinical evidence and issues a binding decision, typically within 45 days.

For immediate needs during the appeals process, Novo Nordisk's emergency insulin supply program can provide up to a 90-day bridge supply while your appeal is pending [21].